Ontada Taps Florida Cancer Data to Fuel National Research Engine

BOSTON, MA – May 21, 2026 – In a move poised to significantly enhance the landscape of cancer research, Ontada, McKesson's oncology technology and insights business, has announced the integration of data from the Florida Cancer Specialists & Research Institute (FCS). The collaboration funnels a massive trove of real-world clinical information from one of the nation's largest community oncology practices into Ontada’s already substantial data ecosystem, promising to provide a clearer, more representative picture of how cancer care is delivered in the United States.

This strategic integration connects rich clinical data from FCS's nearly 100 locations and more than 530 providers with Ontada's advanced analytics platform. The goal is to generate deeper insights that can accelerate the development of new therapies, refine treatment guidelines, and ultimately improve outcomes for patients receiving care outside of traditional academic medical centers.

The Power of Community Data

The vast majority of cancer patients in the United States—around 80%—are treated in community oncology settings. Yet, for decades, much of the data used for clinical research has been drawn from academic institutions, which often have stricter patient selection criteria for trials and may not reflect the diversity of the general patient population. This has created an evidence gap, leaving unanswered questions about how therapies perform in patients with multiple health conditions (comorbidities), those from different socioeconomic backgrounds, or those of varying ages.

By incorporating data from a large-scale community practice like FCS, Ontada aims to bridge this gap. The data provides a window into the real-world treatment patterns, patient journeys, and outcomes that are often missed in the controlled environment of a randomized clinical trial. This type of real-world data (RWD) is increasingly seen as essential for developing a comprehensive understanding of a drug's effectiveness and safety profile.

“By collaborating to integrate FCS’ data into our ecosystem, we are expanding our real-world data to better reflect the realities of community oncology,” said Christine Davis, president of Ontada, in a statement. “This broader perspective strengthens research, informs decisions and supports more personalized, effective care for patients.”

A Strategic Move in a Competitive Data Market

The integration is also a significant strategic maneuver for McKesson, Ontada's parent company, as it seeks to solidify its leadership in the highly competitive oncology data market. Companies like Flatiron Health, Tempus, and IQVIA are all vying to provide biopharmaceutical companies with the data-driven insights needed to navigate the complex drug development and commercialization process. The value proposition lies not just in the quantity of data, but in its quality, depth, and representativeness.

The addition of FCS data substantially bolsters Ontada's offerings. For example, its ON.Dispensing product will now include data from over 270,000 additional oral prescriptions annually, spanning more than 4,000 unique National Drug Codes (NDCs). This provides an unparalleled view into in-office dispensing trends, a critical area of insight for life sciences partners. Other products, such as Clinical DataViews Alerts & Reports and the Real-World Evidence Portfolio, will be enhanced with broader patient cohorts and greater geographic diversity, allowing for the detection of clinical signals and treatment adoption trends earlier than ever before.

This expanded dataset enables Ontada to offer biopharma partners stronger evidence for their research, development, and commercialization decisions. The U.S. Food and Drug Administration (FDA) has increasingly shown openness to using real-world evidence to support regulatory submissions, making high-quality, representative datasets like the one Ontada is building more valuable than ever.

From Data Points to Better Patient Decisions

While the strategic and research implications are vast, the ultimate goal of the collaboration is to directly impact patient care. By analyzing this newly integrated data, researchers and clinicians can better understand how specific treatments work across diverse populations, leading to more personalized and effective care plans.

The insights generated will also power Ontada Learn, a provider education platform. This creates a virtuous cycle: data from community practices informs evidence-based educational content that is then delivered back to clinicians, helping them stay abreast of the latest therapies, testing protocols, and treatment guidelines. This empowers independent community providers with the data-driven advantages typically associated with large, integrated health systems.

“FCS has long been committed to advancing research and improving patient care through real-world data,” stated Lucio N. Gordan, MD, president and managing physician of FCS. “By deepening our collaboration with Ontada, we are strengthening the impact of our data to support evidence generation that benefits patients, providers, and the broader oncology community.”

Navigating the Ethical Data Maze

The aggregation of such vast amounts of sensitive patient information naturally raises questions about privacy and security. In the field of healthcare data, maintaining patient trust is paramount. Ontada, as part of McKesson, operates under strict protocols governed by laws such as the Health Insurance Portability and Accountability Act (HIPAA).

All data used for research purposes is de-identified, meaning that all personal information that could link the data to an individual patient is removed. This process allows researchers to analyze trends and outcomes on a population level without compromising the privacy of any single person. Robust physical, electronic, and administrative safeguards, including data encryption and restricted access policies, are employed to protect the information at every stage. This framework is designed to balance the immense potential of big data to advance medicine with the non-negotiable ethical obligation to protect patient confidentiality.

This integration between Ontada and Florida Cancer Specialists is more than a simple data transaction; it represents a powerful trend in modern medicine. It highlights a shift toward leveraging the collective experience of millions of patients to create a more intelligent, responsive, and personalized healthcare system. By harnessing the power of data from local clinics, the fight against cancer is becoming more collaborative and more effective, accelerating the journey from clinical insight to life-saving treatment.